Clinical Trial Update: Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer [Phase 3]

View source ↗

Summary

Clinical trial entry describing a Phase 3 study of Iseganan Hydrochloride to prevent oral mucositis in patients undergoing radiation therapy for head and neck c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• Iseganan Hydrochloride (iseganan hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer, Oral Complications of Radiation Therapy | Phase 3 | Status: UNKNOWN